drugset / Trial / NCT03811912

Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

NCT03811912

Phase 2 Completed 57 enrolled Concert Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata.

Timeline

Start
2019-03-21
Primary completion
2019-11-21
Completion
2019-11-21

Drugs

EvaluationDrugModalityDoseRoute
Subject CTP-543 Unknown 8 mg
Subject CTP-543 Unknown 16 mg

Indications